No Data
Analysts Have Conflicting Sentiments on These Healthcare Companies: Adaptive Biotechnologies (ADPT), RegenXBio (RGNX) and Ramsay Health Care (OtherRMSYF)
Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns
A Glimpse Into The Expert Outlook On Regenxbio Through 7 Analysts
Goldman Sachs Downgrades Regenxbio(RGNX.US) to Hold Rating, Cuts Target Price to $14
Goldman Sachs Downgrades Regenxbio to Neutral, Lowers Price Target to $14
Raymond James Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $27
HUANG AI : thanks for sharing
magickbeans710 : Thanks man
103567231 : Bro. I saw your post, noticed those colorful ones, but they have already started to skyrocket. I dare not buy. How did you get this information? We are all too late to Buy. Thank you.
Jaguar8 OP 103567231 : Whoever is telling you to buy anyway? It’s your decision and it’s MY WATCHLIST.
Jaguar8 OP 103567231 : Unfollow me and make your own watchlist.
View more comments...